Search results
Results From The WOW.Com Content Network
Rilmenidine, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Rilmenidine shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists, and conferring additional anti-inflammatory actions not shared with most other antihypertensive drugs.
A Comparison of International Guidelines on Goal BP and Initial Drug Therapy for Adults With Hypertension (adapted from JNC 8 guidelines [1] ) Guideline. Population. Goal BP, mmHg. Initial drug treatment options. ESH 2023 [2] General age <65. General age 65–79. General age ≥80.
Guidelines for treating resistant hypertension have been published in the UK and US. It has been proposed that a proportion of resistant hypertension may be the result of chronic high activity of the autonomic nervous system, known as "neurogenic hypertension". Low adherence to treatment is an important cause of resistant hypertension.
Legal status. In Wikidata. Renin inhibitors are pharmaceutical drugs inhibiting the activity of renin that is responsible for hydrolyzing angiotensinogen to angiotensin I, [ 2][ 3][ 4] which in turn reduces the formation of angiotensin II that facilitates blood pressure. [ 5][ 6] Renin inhibitor is often preceded by direct, called direct renin ...
Grade 1 hypertension. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with ...
Moxonidine. Moxonidine ( INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [ 5][ 6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.
Figure 1: The chemical structure of dichloroisoprenaline or dichloroisoproterenol (), abbreviated DCI — the first β-blocker to be developed. β adrenergic receptor antagonists (also called beta-blockers or β-blockers) were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. [1]
Imidazoline receptors are the primary receptors on which clonidine and other imidazolines act. [1] [2] [3] There are three main classes of imidazoline receptor: I 1 is involved in inhibition of the sympathetic nervous system to lower blood pressure, [4] I 2 has as yet uncertain functions but is implicated in several psychiatric conditions, [5] [6] and I 3 regulates insulin secretion.